Payment overview · 2025
General Payments
$706.04
37 reported records · 11 companies
Healthcare provider profile · identity verified
Amy Schreiber, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PALMYRA, PA · NPI 1902195654
Verified facts
What the public records show
CMS Open Payments records show Amy Schreiber, MD received $706.04 in general payments during 2025 across 37 reported records.
GlaxoSmithKline, LLC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $230.14 | 32.6% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $130.64 | 18.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.65 | 14.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.56 | 9.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.72 | 5.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.64 | 4.9% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $30.95 | 4.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.92 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.46 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.36 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $706.04 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $177.83 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.50 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.18 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.88 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $67.97 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.56 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.04 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 80 |
| Losartan Potassium | Losartan Potassium | 287 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 55 |
| Lisinopril | Lisinopril | 206 | 56 |
| Omeprazole | Omeprazole | 202 | 54 |
| Furosemide | Furosemide | 179 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 44 |
| Sertraline Hcl | Sertraline Hcl | 163 | 34 |
| Metformin Hcl | Metformin Hcl | 133 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 43 |
| Trazodone Hcl | Trazodone Hcl | 127 | 32 |
| Gabapentin | Gabapentin | 106 | 37 |
| Simvastatin | Simvastatin | 101 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 31 |
| Mirtazapine | Mirtazapine | 90 | 18 |
| Xarelto | Rivaroxaban | 89 | 11 |
| Lorazepam | Lorazepam | 83 | 35 |
| Buspirone Hcl | Buspirone Hcl | 81 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 19 |
| Potassium Chloride | Potassium Chloride | 69 | 20 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 18 |
| Bupropion Xl | Bupropion Hcl | 60 | 14 |
| Famotidine | Famotidine | 60 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Celecoxib | Celecoxib | 50 | 12 |
| Eliquis | Apixaban | 50 | 15 |
| Meloxicam | Meloxicam | 50 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 19 |
| Atenolol | Atenolol | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Ozempic | Semaglutide | 43 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 29 |
| Tramadol Hcl | Tramadol Hcl | 32 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Budesonide Dr | Budesonide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 17 |
| Lactulose | Lactulose | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Prednisone | Prednisone | 25 | 18 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Valsartan | Valsartan | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $706.04 · 37 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, Auvelity, COMIRNATY, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, FARXIGA, LEQEMBI, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error